REVIEW ARTICLE

Vaccine-Induced Immunity: Unraveling the Secrets of long-Term Protection

Shaik Farahan Subahan[1], Saravanan Ravindran[2]

[1]Department of ???, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India,
[2]Department of Pharmaceutics, Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India

AQ2

Abstract

Objective: This review aims to examine the critical roles of memory B cells (MBCs), memory T cells (MTCs), and long-lived plasma cells (LLPCs) in generating durable vaccine-induced immunity and to evaluate current strategies for overcoming challenges in long-term protection. **Methods:** A comprehensive literature review was performed using databases such as PubMed, Scopus, and Google Scholar. The search focused on molecular drivers of immunological memory, vaccine platforms (Messenger RNA [mRNA], viral vectors, live-attenuated), and recent advancements in computational biology and adjuvant technology. **Results:** Contemporary vaccination success relies on robust immunological memory. LLPCs in the bone marrow sustain humoral defense through continuous antibody secretion, while MBCs and MTCs ensure rapid responses upon re-exposure. Longevity is influenced by the vaccine platform; while live-attenuated vaccines mimic natural infection for superior durability, mRNA and viral vector platforms offer potent induction of both humoral and cellular immunity. Challenges remain for mutable pathogens such as HIV and influenza but are being addressed through heterologous prime-boost regimens, toll-like receptor agonists, and artificial intelligence-driven antigen prediction targeting conserved epitopes. **Conclusion:** Understanding memory cell maintenance and germinal center reactions is vital. Continued research into next-generation delivery systems and computational design is essential for improving the breadth and duration of global vaccine-induced protection.

Key words: Immunological memory, long-term protection, memory B cells, memory T cells, mRNA vaccines, vaccine-induced immunity

INTRODUCTION

A comprehensive and systematic literature search was conducted to identify studies on vaccine-induced immunity. The search was performed across multiple scientific databases, including PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar.

The search strategy employed a combination of primary and secondary keywords. Primary keywords included "Vaccine-induced immunity," "long-term immunity," "immunological memory," and "vaccine efficacy." Secondary keywords were "Memory B cells," "memory T cells," "plasma cells," "humoral immunity," "cellular immunity," and "immunosenescence." The search was limited to the period from 2004 to 2024.

Inclusion and exclusion criteria: Included studies were peer-reviewed original research articles, systematic reviews, and meta-analyses published in English, focusing on human or relevant animal models and discussing long-term protection, memory cells, and immune mechanisms. Editorials, conference abstracts, non-peer-reviewed articles, and studies focusing solely on vaccine safety were excluded.

Vaccines are perhaps humanity's top miracle. They save lives and revolutionize the fight against infectious diseases. Since Edward Jenner's groundbreaking work in 1796, smallpox vaccines have been widely acknowledged as the first vaccines to be developed in the late 18th century. However, Messenger RNA (mRNA) vaccines were created in a hurry during the

Address for correspondence:
Shaik Farahan Subahan, Bharath Institute of Higher Education and Research, Chennai-73, Tamil Nadu, India.
Mobile: +91-8332046091.
E-mail: farasuleman21@gmail.com

Received: 27-02-2026
Revised: 23-03-2026
Accepted: 29-03-2026

AQ1

COVID-19 pandemic. Vaccines train the immune system to recognize pathogens upon re-exposure. The greatest part of it lies in a wonderful biological process known as immune memory. This natural mechanism allows the body's defense system to "remember" all the history of infections so that, once they show up, it can hit them with more effective hits than the first time.[1] How vaccines induce and sustain this memory is essential for unlocking the long-term protection against diseases. The body is protected from infections by the immune system, which is an intricate system of cells, tissues, including chemicals. When a vaccine is introduced into the body, it imitates the infection by providing the immune system with an innocent version of a pathogen or its components (e.g., proteins or genetic material). This leads to the body's signaling event that mounts an immune defense.[2] However, vaccines do not only engineer a transient reaction; they also teach the defense system to remember the pathogen. Memory B cells (MBCs) hence also play a vital role in these scenarios.[3,4] These B cells are formed during the initial response to a vaccine and can persist in the body for years and often for decades. They carry receptors that are built specifically for recognizing the pathogen to which the vaccine applies. When this pathogen re-enters the scene, they spring into action, dividing rapidly and generating antibodies to neutralize the threat.[5,6] This rapid response – also known as secondary immune response – is much more rapid and effective than the body's first experience with the pathogen and is capable of providing a very powerful shield against infections.[7] Memory T cells (MTCs) fall under two major types, namely T helpers Cells and Cytotoxic T cells function as coordinators for other cells and boost antibody production while Cluster of Differentiation 8 positive ($CD8^+$) T cells operate as the body's assassins: They track down and kill cells that have been penetrated by the pathogen, effectively leaving the latter with no chance to propagate.[8] MTCs will long survive, still issuing a quick response if the pathogen comes back. Immune memory's unsung heroes are long-lived plasma cells (LLPCs); one can identify which are mostly found in the bone marrow.[9] These cells continuously produce antibodies specific to the vaccine antigen, thus providing a steady level of protection, even as there may not be any sign of infection. The main antigen-presenting cells (APCs) that connect immune system responses that are innate and adaptive are dendritic cells (DCs). In the respiratory tract, they collect inhaled pathogens and go to the nearby lymph nodes, where they expose naïve T lymphocytes to processed antigens. Pathogen-specific T and B cells, which are essential for long-term protection, spontaneously activate as a result of this interaction, which starts and attracts the aberrant adaptive response. DCs release cytokines and co-stimulatory signals to affect the type and intensity of the immune response in addition to activating and starting the adaptive immunity. Antibodies are always there and ready to act and will neutralize pathogens before they can do any harm.[10] There are several determinants of vaccine-induced immune memory regarding strength and duration such as types of vaccines, the nature of pathogens, and personal differences in immune capability. Taking live attenuated vaccines as an example, which use weakened portions of a pathogen, it is easily observed that live-attenuated vaccines offer stronger and longer-lasting immunity when compared to inactivated or subunit vaccines. Since the immune system mimics a natural infection, it engages itself more comprehensively when using live-attenuated strains. On the contrary, subunit vaccines – they have only parts of a pathogen – may require adjuvants or booster doses to produce similar levels of protection as that provided by the live-attenuated vaccine. Adjuvants enhance immune function in vaccines by making the body react well to the readied innate immune system, which allows vaccines to evoke controlled inflammation, summon immune cells, and activate them.[11] This way you have a stronger, more quality immune response that produces even more antibodies and helps form those long-lasting memory cells. Advances in vaccine technology also improved our understanding of immune memory-they opened up broader avenues for vaccine design.[12] Examples of radically new advances in this regard are mRNA vaccines. Unlike traditional vaccines, which deliver the antigen directly to the body, mRNA vaccines give the body's cells the genetic instruction to produce the antigen themselves. This not only mimics natural infection more closely but also allows for rapid adaptation should the pathogen change, as was the case with the rapid development of vaccines for COVID-19. The breakthrough in improving vaccines has not yet been achieved, and more research into understanding the puzzles that keep immunity memory elicitation elusive from developing vaccination will need to take place.[13] The finding of immune memory secrets will not only inform the progress of future vaccines, which will offer broader and more durable protection, but it can also lead to the identification of new intervention targets and the development of more potent adjuvants, as well as the development of innovative vaccine platforms that will overcome current limitations. This information can be harnessed to support public health by informing optimal decisions about vaccination schedules, booster doses, and how best to protect vulnerable populations.[14] In summary, vaccine-induced immune memory is a cornerstone of immunization strategies today.

MECHANISMS OF MEMORY CELLS IN CELL FORMATION, THEIR MAINTENANCE, AND PART IN IMMUNIZATION-INDUCED IMMUNITY

Vaccines constitute superior medical treatments in reducing the disease and death levels due to transmissible diseases. The aspirational goal of vaccination is lifelong immune protection, which is undertaken by MBCs and MTCs. The memory cells prepare the immune system for rapid and vigorous reaction by preventing or reducing disease upon re-exposure to the disease.[14] The generation and maintenance of these memory cells are prerequisites for the durability and efficacy of vaccine-induced immunity. MBCs produce antibodies with

AQ1

high affinities while T cells respond to antigen exposure with cellular immune responses that are more rapid and effective. Factors for this include antigen, vaccine composition, germinal center (GC) activity, cytokine signatures, and metabolic adaptations. The knowledge of these pathways is important for unique vaccine designs, especially in lifelong protection against influenza, tuberculosis (TB), human immunodeficiency virus, and newly emerging infectious diseases such as COVID-19.[15]

MBC FORMATION, HOMEOSTASIS, AND ACTIVITY

MBC generation is triggered by activation of the native cells in the peripheral lymphoid organs. That is when a B cell binds an antigen and receives other signals from a helper T cell and particularly from different accessory cell types such as DCs to activate it.[16,17] MBCs are produced by Germinal cells in either GC-dependent or GC-independent pathways. GC-independent MBCs, primarily immunoglobulin (Ig) M-positive/CD73$^+$ memory cells, are produced through an early extrafollicular response. Despite being of lower affinity than GC-derived MBCs, these cells quickly respond to antigen re-exposure, providing a rapid line of defense. On the other hand, GC MBCs undergo class-switch recombination and affinity maturation to generate memory cells capable of executing strong, long-lived immune responses: Ig class IgG$^+$ or class IgA$^+$. Cytokines influence and shape these pathways. In B and T cells, B cell lymphoma 6 (Bcl-6) expression is interleukin (IL)-21-dependent, with IL-21 being mainly secreted by T follicular helper (Tfh) cells. In B cells, Bcl-6 promotes somatic hypermutation (SHM), class switch recombination, proliferation, and GC formation. In T cells, IL-21 functions in Tfh lineage maintenance and sustenance. IL-2 is linked with effector T cell growth and is also required for Tfh development through altering the expression of transcription factors that control lineage commitment. These procedures enhance B cells' ability to generate antibodies. Eventually, the B cells that have a high attraction for the antigen will either become B cells or LLPCs, which secrete antibodies continually.[18] In contrast, the GC-independent pathway generates early MBCs outside GCs. Collectively, these cells may display weaker affinities for the antigen, but they respond more quickly upon reexposure. Overall, this pathway allows the diversity of B cells, being especially significant for the initial immune response. There are various factors that are thought to influence long-lasting memory, apoptosis, and survival of B memory cells that have been studied in detail. Cytokines and signals mediating survival are among these factors.[19] MBCs are also found in some other locations in the body, such as peripheral organs, lymphoid tissues, and the circulation. Some of MBCs would reside in certain organs, like intestines and lungs, providing localized immunity with rapid response-infection at mucosal surfaces.[20] When exposed again to antigens, these cells do not produce antibodies in the same way a plasma cell does. On reinfection, however, they multiplied to antibody-producing plasma cells, generating a strong secondary immunological response. Furthermore, MBC lifespan requires repeated exposure to antigen, resulting from either booster vaccination or spontaneous infection. Booster doses ensure continuity of immunity through MBC reactivation.[21] This is particularly true for vaccines associated with weak initial immune reactivity, such as inactivated or subunit vaccines. MBCs are vital for humoral immunity since they produce high-affinity antibodies after re-exposure to the antigen.[22] Only those cells, specifically make contact with the antigen survive long term, having been subjected to affinity maturation and SHM in GCs. Some develop into latent MBCs waiting for antigen confrontation, while others turn into LLPCs and secrete antibodies continually. MBCs rapidly proliferate and differentiate into plasma cells upon the resurgence of a pathogen in the body, thus producing high amounts of antibodies. Such a response is immediately effective in providing protection from the re-infection but proves to be much faster than the first response.[23] Booster shots are then required periodically to maintain these populations of MBCs and high antibody levels.[24] Vaccines such as live attenuated and mRNA vaccines induce a strong GC reaction by the formation of potential B cells.

MTC FORMATION, HOMEOSTASIS, AND ACTIVITY

These cells provide a long-standing cellular immune protection upon vaccination; hence, forming the backbone of vaccine-induced immunity. Naïve T lymphocytes begin to evoke immune responses once they recognize the antigen presented by APCs and DCs.[25] Both signals for co-stimulation bear down on the already-present antigen to achieve T-cell priming and specialization. Active T cells wipe the infection first, then begin the conversion into memory cells once the pathogen is eliminated from the body. Now, those MTCs will rapidly react to reinfection and can maintain a long period of viability in the body. T_EM quickly responds to antigen stimulation by producing cytokines in circulation through the blood and peripheral tissues.[26] T_CM expresses CCR7 and CD62L that enable their recirculation to lymphoid tissues and quick response to re-exposed antigens. T_EM can elicit an immune response quite rapidly without extensive proliferation when faced with infection. Another type, T_RM, is found in non-lymphoid tissues such as skin, intestine, and lung.[27] These cells generate quick, local immunity at the site of infection without the need for recirculation. The T_RM cells provide the first line of immunological defense, aided by their ability to stay in tissues and express markers such as CD69 and CD103. MTC sustenance is secured under several processes including metabolic adaptation and cytokine support; they are homeostatically maintained by cytokines such as IL-7 and IL-15, which support both persistence and balanced growth. Cell development and longevity are also regulated by IL-2, which comes from the initial immune response.[28] A sophisticated network of signals coordinates

AQ1

the development and upkeep of MTCs. T cell factor 1 serves as a fundamental component that facilitates central MTC self-renewal and lymphoid tissue homing, allowing for long-term maintenance. While Blimp-1 encourages effector cell fate and drives T cells toward prompt rather than delayed responses, Bcl-6 strengthens the memory cell by suppressing genes linked to final effector differentiation. These results are further explained by the interaction between T-bet and eomesodermin (Eomes); higher levels of eomes and lower levels of T-bet are linked to improved MTC survival. To ensure effective migration back to lymphoid organs, FoxO1 controls the quiescent state of MTCs and stimulates the expression of homing receptors including CD62L and CCR7. The Id2 and Id3 proteins have a pivotal role in deciding the lineage commitment, with Id3 resulting in differentiation of MTCs. When it comes to metabolism, MTCs primarily rely on mitochondrial fatty acid oxidation to maintain their life, while effector T cells rely on glycolysis to meet their quick energy demands. The mechanistic target of rapamycin signaling pathway is also necessary, as it induces effector differentiation, whereas inhibiting it promotes the production of memory cells. Cytokines like IL-7 and IL-15 are needed for keeping MTCs alive and aiding their ability to self-renew and ensure a beneficial.[29]

It seems this metabolic change in the body without being reactivated by antigens. This cellular immunity relies on the MTC capacity to assist in pathogen clearance and immunological vigilance.[29,30] After vaccination, native T cells find tissue-resident effector T cells while recognizing APC-displayed antigens. Following pathogen clearance, the majority of the effector cells die, but some persist as MTCs for years.[31,32] Three subtypes are within tissue-resident memory T cells (T_RM), effector memory T cells (T_EM), and central memory T cells (T_CM). Upon secondary antigen encounter, T_CM cells residing in the lymphoid tissue proliferate and differentiate into effector T cells. In contrast, the T_EM cells are responsive to cytokines and are found in the blood circulation and peripheral organs for the fast immune response. T_RM cells impart localized immunity by being detected in non-lymphoid tissues. Cytokines protect and sustain immune cells for survival and self-renewal. Long-lasting cellular immunity becomes a reality when the intense T-cell response activated by the vaccines favors the formation of MTCs.[33,34]

ROLE OF VACCINE ADJUVANTS IN ENHANCING VACCINE-INDUCED IMMUNITY

An adjuvant is an immunostimulatory agent added to a vaccine to improve and sustain immune responses, thereby helping to maximize antigen presentation and stimulate innate immunity as well as strong adaptive immune responses, culminating in long-lasting immune memory. In particular, in subunit, killed, and recombinant vaccines, which may lack the intrinsic immunogenicity found in live, attenuated vaccines, adjuvants play a role in bolstering up antigen presentation by enhancing antigen uptake, processing, and presentation by APCs, particularly DCs.[36,37] Adjuvants stimulate pattern recognition receptors (e.g., toll-like receptors [TLRs] and NOD-like receptors), upregulating co-stimulatory molecules (CD80 and CD86) and MHC, enhancing naïve T-cell priming and adaptive immunity.[38] They also create antigen depots to allow for prolonged immune stimulation and activation of memory cells, which are critical players in continuous immunity. An adjuvant such as alum, a slow-release carrier, favors prolonged immune responses; however, alum adjuvants induce more Th2-type responses that trigger antibody production, especially IgG1 and IgE. Adjuvants modify the balance among Th1, Th2, and sometimes Th17 responses to AI in the production of pathogen immunity by vaccine. Alum initiates the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), resulting in secretion of pro-inflammatory cytokines IL-1β and IL-18, which favor Th2-type immune responses. Alum gets retained as a commonly used adjuvant; recent vaccine adjuvants have expanded and describe more targeted immune modulators. For example, CpG oligodeoxynucleotides, which are TLR9 agonists, are used in the Heplisav-B vaccine and promote a Th1-biased response, enhancing cytotoxic T-cell activity and the production of opsonizing antibodies for improved pathogen clearance. The memory response is enhanced by adjuvants through the differentiation and survival of memory cells. Adjuvants that activate immune cells develop memory plasma cells in the bone marrow and undergo rapid differentiation into MBCs that can recall antigens upon subsequent exposure. Adjuvants stimulating T cells promote memory cytotoxic T lymphocytes (CTL) formation, ensuring long-term antiviral immunity.[39] Many clinically approved adjuvants underscore the full manifestations of these processes. Aluminum salts (alum) are commonly used in vaccines, including those against diphtheria, tetanus, and hepatitis B, as they may enhance humoral immunity. Oil-in-water emulsions such as MF59 (used in influenza vaccinations) and AS03 (for pandemic flu vaccines) increase antigen retention and promote vigorous immune responses. QS-21, used in the vaccine against herpes zoster, represents a saponin-based immunoadjuvant that enhances cellular immunity by enhancing T-cell responses.[40] The production of new adjuvants involving TLR agonists and nanoparticle-based delivery avenues will eventually maximize both efficacy and longevity while securing long-lasting protection from infectious diseases.

LONG-TERM IMMUNITY WITH VIRAL VACCINES AND MRNA VACCINES IN COMPARISON TO TRADITIONAL VACCINES

In contrast to traditional vaccines, the introduction of mRNA and viral vector vaccines provides a more effective

AQ1

and flexible way to induce immunological memory and constitutes a paradigm shift in the area of vaccine research. These platforms have demonstrated good immunogenicity, good scalability, and very rapid time-to-development, with the best examples being the mRNA vaccines and viral vector vaccines.[41] Due to their ability to induce strong and long-lasting immune responses, they are now becoming important tools against newly emerging infectious diseases. Synthetic messenger RNA encoding a viral antigen is injected into the body through mRNA vaccines; the mRNA is usually protected and facilitated into cells through lipid nanoparticles (LNPs). Following entrance into the cytoplasm, the viral proteins produced by host ribosomes are processed and presented by MHC receptors found on APCs. This results in strong proliferation of $CD4^+$ supporter T cells and the compound $CD8^+$ cytotoxic T cells in addition to enhancing memory B-cell responses.[42] mRNA allows highly regulated and temporary expression of the antigen due to its rapid degradation and lack of integration into the host genome. Alternatively, viral vector vaccines employ genetically engineered viruses, including adenoviruses, to carry the viral antigens. These vectors express the target antigen following entry into host cells, thus stimulating an immune response. As the viral pathways serve as natural adjuvants, the pro-inflammatory cytokines elevated levels induced, viral vector system, as opposed to mRNA vaccines, induce a greater innate immune response, which further assists in the development of adaptive immunity.[43] Certain viral vectors, for instance, wherein the adenoviral vectors are non-replicating and, therefore, strongly immunogenic but cannot replicate like regular viral vectors to cause damage. Conventional inactivated vaccines, like those for polio and hepatitis A, contain viral particles that have been destroyed and primarily work by eliciting humoral responses to boost immunity. Inactivated vaccines require adjuvants and boosters for durable immunity, unlike live-attenuated vaccines such as Measles, Mumps, and Rubella (MMR) and yellow fever vaccines. Live-attenuated vaccines induce strong humoral and cellular immunity through viral replication. Despite the effectiveness of these vaccinations, potential return of virulence exists, particularly in immunocompromised individuals.[44] A distinct advantage provided by mRNA and viral vector vaccines is stimulation of both humoral and cellular immunity. Viral endogenous expression in host cells facilitates effective antigen presentation pathways, producing potent $CD8^+$ T cell responses that are often less pronounced in conventional inactivated vaccines. In addition to this, the ability to modify the mRNA sequences to regulate immune responses is most likely facilitated better through this design control. Immune memory is dictated by the capacity of the memory cell populations to retrieve the information in a timely manner after re-exposing the organism to the same pathogen.[45] The long-term immunity was therefore induced using live-attenuated vaccines, which limit viral replication and expose the host to antigens persistently. On the contrary, inactivated vaccines lead to weakened memory responses and the need for recurrent booster doses. Preliminary evidence suggests that there may be long-term memory effects induced by viral vector and mRNA vaccines. Studies of COVID-19 mRNA vaccines induced strong memory cell and bone marrow plasma cell responses, indicative of long-lived antibody responses. Viral vector vaccines have induced strong T-cell immunity, crucial for intracellular pathogens such as coronaviruses and Ebola. However, pre-existing immunity against viral vectors such as adenoviruses can occasionally reduce efficacy by enabling rapid clearance of the vector by the immune system before antigen expression.

Viral vector pre-existing immunity solutions

Pre-existing immunity to viral vectors, often encountered through prior natural infections or prior vaccinations, can significantly reduce the effectiveness of gene therapy or vaccination strategies using those vectors. Several approaches are being explored to overcome this challenge, including using alternative vector serotypes, modifying vector design, and employing prime-boost vaccination strategies.

Understanding pre-existing immunity

Humoral immunity

Antibodies, particularly neutralizing antibodies (NAbs), can bind to viral vector particles and prevent them from entering target cells, thus hindering gene delivery or vaccine efficacy.

Cellular immunity

T cells, especially CD8+ CTLs, can recognize and destroy cells infected with the viral vector, limiting the duration and extent of gene expression or immune response.

Innate immunity

The innate immune system can also recognize viral vector components, leading to inflammation and the production of interferons (IFNs), which can interfere with transduction and reduce the desired immune response.

Strategies to circumvent pre-existing immunity

Alternative vector serotypes

Using different serotypes of the same virus (e.g., different adenovirus serotypes) that humans have not been previously exposed to can help avoid pre-existing immunity.

Vector modification

Capsid Modification: Altering the vector's capsid (the protein shell) can change its ability to be recognized by antibodies and other immune components, reducing neutralization or immune cell targeting. Tissue-specific Promoters: Using promoters that are active only in specific cell types can help to reduce the immune response against the vector itself, particularly in APCs.

AQ1

Prime-boost regimens

Using a combination of different viral vectors or different routes of administration (e.g., intramuscular [IM] followed by intranasal) can help to generate a stronger and more durable immune response, potentially overcoming pre-existing immunity.

Immunomodulation

- Adjuvants: Adding adjuvants to the vaccine can boost the immune response and enhance the effectiveness of the viral vector
- Immunosuppressants: In some cases, short-term use of immunosuppressants can be used to dampen the immune response against the vector, allowing for better gene delivery or vaccine efficacy.

Targeted delivery

Developing methods to deliver the viral vector directly to the target tissue or cells can minimize exposure to the immune system and reduce the impact of pre-existing immunity.

Examples of applications

Gene therapy

AAV vectors are commonly used for gene therapy, and strategies to overcome pre-existing immunity are crucial for successful and widespread application.

Vaccines

Viral vectors are used in several vaccine platforms, and pre-existing immunity to the vector can be a limiting factor. For example, adenovirus vectors are used in some COVID-19 vaccines, and strategies to overcome pre-existing immunity are being explored.

FUTURE DIRECTIONS

Further research is needed to fully understand the complex interplay between the immune system and viral vectors.

Developing new, more sophisticated strategies to circumvent pre-existing immunity is crucial for advancing the field of gene therapy and viral vector-based vaccines.

Combining different approaches, such as vector modification and prime-boost regimens, may offer the best chance of overcoming pre-existing immunity and maximizing the benefits of viral vector technology.

Different vaccine platforms are associated with varying safety characteristics. While inactivated vaccines are generally safe, the introduced adjuvant components could cause discomfort at the injection site.[46] Rarely, mild infections and reversion to virulence may result from the administration of weak pathogen vaccines. Vaccines from mRNA vaccines have demonstrated outstanding safety profiles and are associated with transient systemic adverse effects, mainly due to stimulation of the natural immunity, including fever, malaise, and muscle soreness. The risk of insertional mutagenesis is eliminated with mRNA since it is rapidly degraded and does not integrate into the genome. In as much as they are safe, there have been very few cases of vaccine-induced thrombotic thrombocytopenia attributed to viral vector vaccines, particularly those using adenoviral platforms. The protracted timeline for manufacture has remained a major drawback for traditional vaccines, particularly live-attenuated vaccines, because they need lengthy and complicated cell culture procedures.[47] The manufacturing cost of inactivated vaccines is further elevated with many rounds of lengthy purification. mRNA vaccines are greatly advantageous in terms of their rapid scale-up for manufacture. As shown during the COVID-19 pandemic, they may be swiftly created and produced using chemical synthesis without the need for live viral culture. Their chief disadvantage, however, is the need for ultra-low temperature (−70°C for Pfizer-BioNTech) for storage, rendering distribution logistically problematic in resource-poor settings.[48] This restriction is being actively countered by advances in thermostable formulations. Viral vector vaccines will, in contrast, be much more viable for global distribution since they are simpler to manufacture.

BOOSTER DOSING AND LONG-TERM IMMUNOLOGICAL MEMORY RECALL IN VACCINES

For long-term infectious disease protection, vaccines induce immunological memory. However, as time passes, immunologically protective responses weaken or fade, requiring booster doses to restore the memory of the immune system. Booster doses enhance memory B and T-cell responses, providing long-term protection after booster immunizations reintroduce the immune system to the antigen.[55] The effectiveness of booster doses depends on the type of vaccination, the durability of the antigen, and the immunological status of the recipient. Following immunization, APCs digest and deliver antigen to unaware T and B cells, generating memory cells. With time, memory cells may become quiescent, and antibody levels may fall. Booster doses also activate MTCs, which are critical for cellular protection from viruses and other intracellular infections. Booster doses enhance SHM and selection in B cells.[56] These cells will undergo SHM in GCs as a result of repeated exposure to the antigen, thus favoring clones with higher-affinity antibodies. The process consequently ends up yielding a stronger, more efficient immune response for every additional booster. This is particularly beneficial for individuals with compromised immune systems and the older population, whose immune system deteriorates more quickly. The interval between booster vaccinations is determined by the duration of immunologic memory established after the initial vaccination series.[57]

AQ1



AQ3 **Figure 1:** Vaccine-induced immunity



AQ3 **Figure 2:** Detailed metabolic pathway diagram for T-cell memory

HETEROGENEOUSLY PRIME-BOOST STRATEGIES

This heterologous prime-boost approach permits the combination of different vaccine types for priming (first) and boosting (subsequent) doses to achieve optimal immune responses. This very promising approach has drawn considerable attention in vaccination science because it has been shown to yield improved immunogenicity, broader immune coverage, and extended duration of protection over homologous (same type of vaccine) regimens. Modes of stimulating the immune system differ with different types of vaccines: combining vaccinations stimulating different immune pathways synergistically improves immune memory.[58] For instance, viral vector vaccines (AstraZeneca, Sputnik V) are strong promoters of cellular immunity through activation of T cells, while mRNA vaccines (Pfizer-BioNTech, Moderna) generate very strong antibody responses relative to high-affinity B-cell memory. Final subunit protein vaccines (e.g., Novavax) have an emphasis on humoral immunity, even though they require an optimal adjuvant for T cell activation.

AQ1



AQ3 **Figure 3:** Hematopoietic stem cells differentiate into B, T, and NK cells[35]



AQ3 **Figure 4:** Pfizer-BioNTech COVID-19 vaccine

BENEFITS OF HETEROLOGOUS PRIME-BOOST STRATEGIES

Enhanced immunogenicity

Studies with COVID-19 vaccines have shown that heterologous dosing – immediate antibody and T-cell responses – will be produced with priming through one type of vaccine and a boost through another, as opposed to two doses of the same vaccine.[59]

Broader immune coverage

Using a variety of vaccinations, then, has extended immune responses, more effective against changing infections and changing viral forms. This is especially so for fast-changing viruses such as influenza and coronaviruses.[60]

Improvement in vaccine efficacy

In special populations: Some individuals, particularly the elderly and those with lesser-impaired immune systems, may not develop sufficient immunity with one type of vaccine. Weaker responses can then be compensated for by heterologous boosting.[61]

Improved GC responses and long-term humoral immunity

By successively activating different innate sensors, heterologous vaccination improves GC responses, resulting in enhanced affinity maturation, extended antibody production, and a more resilient pool of MBCs and LLPCs.

Flexibility in vaccination deployment: Heterologous approaches allow interchangeable vaccine regimens in the time of pandemics or supply shortages, thus ensuring better access to vaccines and avoiding disruption in immunization campaigns.[62]

EXAMPLES OF STRATEGIES FOR BOOSTER DOSING

Routine childhood vaccines

Booster doses have markedly increased neutralizing antibody levels with the mRNA vaccines (Pfizer-BioNTech, Moderna) for refurbished protection against severe disease. For example, the diphtheria, tetanus, and pertussis vaccine is administered in multiple doses between infancy then booster

AQ1



AQ3 **Figure 5:** Heterologous Severe Acute Respiratory Syndrome Coronavirus 2 vaccine platform[63]

shots are given during adolescence and adulthood to sustain protective immunity.[64]

COVID-19 vaccines

Results from studies have indicated that immunity due to primary COVID-19 mRNA vaccines starts to wane over time, especially in nexus with upcoming variants.[65]

Vaccine for hepatitis B

While the first vaccination set produces strong protection, certain risk groups, such as healthcare workers, might need a booster as their levels of antibodies significantly drop soon thereafter.

Human papillomavirus (HPV) vaccine

In most cases, the HPV vaccination is given in a series of doses to ensure sustained immunological memory against the carcinogenic strains of HPV.[66]

CORRELATES OF PROTECTION: LONG-TERM IMMUNITY BIOMARKERS

The exploration of the immunological markers that predict long-term protection after an immunization is significant for determining optimum vaccine design and schedule of booster doses and evaluation of overall efficacy. A measurable immunological metric qualified as a correlate of protection (CoP) becomes a good marker for immune measurement. These indicators will reflect the duration of memory over time of immunological memory induced through vaccination, as well as the possibility of an individual continuing to be protected from disease over time.[77] The binding of high-affinity NAbs to key surface proteins on a specific pathogen to block viral entry is among the well-known indicators. High levels of NAbs correlate well with protection from COVID-19, influenza, and measles viruses. However, they wane with time, and hence the concern for waning immunity. MBCs provide long-term protection, surviving long after antibody titers go down, and quickly produce high-affinity antibodies upon re-exposure. Measurements of MBC responses by enzyme-linked immunospot are a more accurate assessment of persistent immunity than antibody titers by themselves. Therefore, cellular immunity is as significant as humoral immunity in establishing long-lasting protection.[78] After reinfection, T cells aid in the pathogen's rapid removal. T lymphocyte responses and the generation of cytokines are most commonly monitored using flow cytometry-based techniques or gamma IFN (IFN-γ) release assays (IGRAs). Another significant criterion is that of functional antibody activity: these pathways improve pathogen clearance through interaction with effector immune cells.[79] Memory for $CD45RA^{+}/CCR7^{-}$ effectors. When re-exposed to pathogens, T cells that re-express RA (T_{EMRA}) are a terminally differentiated subpopulation that can produce quick effector responses. These cells are very crucial for protection against viruses. In addition, since they coordinate several immune functions and have a higher capacity for cytotoxicity, polyfunctional T cells – which produce multiple cytokines at the same time, including IFN-γ, tumor necrosis factor-alpha, and IL-2 – are linked to superior protective immunity. For long-term defense against intracellular pathogens like viruses, profiling these subsets can yield important information about the caliber of vaccine-induced memory. Mucosal IgA responses are especially reserved for bacterial vaccines because they give localized defense at the sites of infection as in rotavirus and pneumococcal vaccines. Each disease does not have the same correlates for protection, and to evaluate the efficacy of vaccination, various biomarkers are usually needed.[80] For example, the

protection of hepatitis B vaccination is indicated by serum anti-HBs antibody levels, while T lymphocyte immunity is vital for TB vaccines. In addition, new vaccination platforms such as viral vector and mRNA vaccines generate even further challenges regarding the identification of CoP because they induce distinct humoral and cellular responses.[81] Although much progress has been made in finding immunological markers, the definition of universal correlates of protection remains elusive. Continual study must improve predictive biomarkers since much will vary from individual immune responses to the effects of mutations of viruses to differences in vaccination platforms.[82] Future integrative approaches will provide a more comprehensive assessment of immunity over the long term in vaccine development with investigations that involve serological, cellular, and functional immune markers.

FACTORS INFLUENCING LONG-TERM VACCINE-INDUCED IMMUNITY AND STRATEGIES TO OVERCOME THEM

Vaccine platform type

The immunological responses provoked by various vaccination platforms are different from each other. In general, live-attenuated vaccines elicit strong and long-lasting immunity through simulated natural disease (for example, MMR and yellow fever), while the inactivated ones (for example, polio and hepatitis A) sometimes require booster doses for there is lowered immune memory. Both mRNA and viral vector vaccines are highly potent, but they would need a number of boosts to sustain immunity. Advances in vaccine technology, including next-generation adjuvants and nanoparticle-based vaccines, promise to improve and extend inferior immune responses on other vaccine platforms.[83]

Strength of initial immune response and duration

Immunity develops over a period based on the intensity of response, especially the initiation of cells. Vaccines that produce strong T-cell responses and high-affinity antibodies promise longer-lasting protection. However, various other factors such as age, genetics, and pre-existing immunity can affect the responses. Heterologous prime-boost strategies (mixing types of vaccinations), optimizing the prime-boost regimen, and adjusting antigen dose can be applied to enhance immune durability.[84]

Response of intervals and persistence of antigens

Some vaccines can activate the immune system several times in the presence of a long-time antigen. Vaccination with short-lived antigens might need to have booster doses several times to maintain effective immunity. Many slow-release antigen delivery methods including viral-like particles or polymer-based nanocarriers will improve persistence while minimizing the number of repeat booster shots.[85]

Variability of pathogens and immune evasion

Rapidly changing viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), HIV, and influenza, escape from the immune detection and ultimately become ineffective. Every year, the vaccine formulation revision is necessary due to antigenic drift and changes in the influenza viruses. Universal vaccines that target conserved portions of the viral proteins – for example, the S2 subunit in coronaviruses or the hemagglutinin stalk in influenza – could offer more comprehensive and long-lasting protection. Broad-spectrum protection against diverse viral variants remains a critical objective in the pursuit of universal vaccine strategies, focusing on conserved viral elements such as the S2 domain in coronaviruses or the hemagglutinin stalk in influenza viruses. Yet, eliciting robust and neutralizing immune responses against these conserved regions proves challenging; such epitopes are often structurally concealed or exhibit limited immunogenicity. Addressing these biological hurdles is fundamental to the advancement of next-generation vaccine development.[86]

Immunosenescence and age

Age-related immune declines generally affect natural and developed immune responses alike. Due to chronic inflammation, reduced action, and limited variability in memory cells, older persons mostly show reduced response to vaccination. The following is a strategy to counteract age-related immune decline: Frequent booster doses, adjuvanted vaccinations (such as AS03-adjuvanted flu vaccines), and high-dose vaccines (like Fluzone High-Dose for influenza). People's immune systems significantly deteriorate with age. T and B cells lose their potency, and senescent immune cells build up, impairing general function. In older persons, this weakened immune response frequently leads to a decline in the effectiveness of vaccinations. Recent therapies, such as senolytic adjuvants like navitoclax, have a lot of promise since they can improve vaccine results in the elderly population by reviving immune activity by specifically removing old, malfunctioning cells.[87]

Individual and genetic variability

Individual variations in medicine respond to different vaccine results. Some forms of immunity among individuals respond very well to vaccines because of often different human leukocyte antigen (HLA) genes, cytokine profiles, and receptor expressions. Furthermore, some configurations of immunity generated by these vaccines could be lessened due to many other diseases such as immunodeficiency, chronic illnesses, and malnutrition. Personalized vaccination

AQ1

AQ8

Table 1: Comparison between mRNA vaccine, viral vector vaccine with traditional vaccines

Feature	mRNA vaccines	Viral vector vaccines	Traditional vaccines (inactivated/live-attenuated)	References
Technology	Uses synthetic mRNA to encode an antigen	vector to deliver genetic material	Uses killed or weakened pathogens	[46-55]
Examples	Pfizer-BioNTech, Moderna	AstraZeneca, Johnson and Johnson, Sputnik V	Polio, Measles, Mumps, and Rubella, Influenza, Hepatitis A/B	
Mechanism of action	mRNA directs antigen synthesis, inducing an immune response.	Rare vectors, adjuvants, RNA, targeting, and multivalent or mucosal delivery.	Direct antigen introduction (inactivated) or replication in the body (live-attenuated)	
Antigen presentation	Cross-presentation activates MHC-I and $CD8^{+}$T cells.	Endogenous (through host cell machinery)	Exogenous (direct presentation to immune cells)	
Type of immunity induced	Strong humoral and cellular (CD8+T cells)	Strong humoral and cellular (CD8+T cells)	Primarily humoral (CD4+T cells for inactivated, strong CD8+for live-attenuated)	
Speed of immune response	Rapid antibody and T-cell response	Slower than mRNA but robust	Slower for inactivated; live-attenuated provides rapid response	
Stability and storage	Requires ultra-cold storage (−70°C for Pfizer)	Requires refrigeration (2–8°C)	Stable at standard refrigerator temperatures	
Duration of immunity	Greater than or equal to 6 months, boosters required to exceed 12 months	6–12 months, boosters required	Lifelong (live-attenuated), several years (inactivated)	
Booster requirement	Required due to waning immunity	Required due to waning immunity	Varies; some require boosters, some do not	
Efficacy against variants	Reduced against some variants, boosters improve protection	Varies based on vector stability and mutations	May require reformulation for evolving pathogens	
Safety profile	Mild side effects; rare myocarditis and anaphylaxis cases	Mild side effects; rare blood clot cases (J&J, AstraZeneca)	AS03-adjuvanted H1N1 influenza vaccine (Pandemrix) was linked to narcolepsy in select populations	
Manufacturing complexity	Requires complex lipid nanoparticle formulation	Requires viral vector engineering	Traditional manufacturing; well-established	
Scalability and production	Rapid, but high-cost and complex storage	Easier to scale with traditional vaccine facilities |	Easily scalable with existing technology	
Acceptance according to the WHO survey	70–85%	60–75%	50–70%	
Regulatory approval	Emergency use followed by full approval	Emergency use followed by full approval	Fully approved for most traditional vaccines	

mRNA: Messenger RNA, CD: Cluster of differentiation

strategies, such as dosage adjustments, applying different delivery systems (such as intradermal vaccinations for a more potent antigen presentation), and genetic screening of vaccine non-responders, would be the best to maximize Immunity.[88]

Route of administration

Administering a drug determines the extent of immune response. Mucosal vaccines (for example, nasal influenza vaccine and oral polio vaccine) would induce more or less restricted immune protection at the entry points, whereas IM injection usually leads to systemic immunity. It is worth mentioning here that local mucosal immunity may be the best protective measure against certain infections, for example, the respiratory viruses. Intranasal vaccinations are designed to produce robust immune responses, with a focus on preserving secretory IgA (sIgA) synthesis in the intranasal epithelium. It eliminates infections. In order to control sterilizing immunity and

AQ1

AQ8

Table 2: Comparison between long-term immunity vaccines

Vaccine	Disease prevented	Type of vaccine	Mechanism of action	Immunity period	Booster/Memory
Varicella (Chickenpox)	Chickenpox	Live-attenuated virus	Induces strong B and T-cell responses	Lifelong in most cases	Not routinely required, but booster available
Yellow Fever	Yellow Fever	Live-attenuated virus	Induces long-lived antibody response	At least 10 years, often lifelong	Booster needed in high-risk areas
Hepatitis B	Hepatitis B	Recombinant protein	Induces strong humoral immunity through hepatitis B surface antigen	>20 years, possibly lifelong	Booster recommended for immunocompromised individuals
Human Papillomavirus (HPV)	Cervical and other HPV-related cancers	Recombinant protein (virus-like particle)	Induces neutralizing antibodies against HPV	At least 10–15 years, potentially lifelong	No booster currently recommended
Polio (inactivated poliovirus virus [IPV])	Poliomyelitis	IPV	Induces systemic immunoglobulin G (IgG)-mediated immunity	Lifelong after full dose series	No booster needed unless traveling to endemic areas
Diphtheria, Tetanus, Pertussis	Diphtheria, Tetanus, Pertussis	Toxoid (D&T), Inactivated (P)	Induces strong antibody response against bacterial toxins	~10 years	Booster required every 10 years (Tdap/Td)
Bacillus Calmette-Guérin	Tuberculosis	Live-attenuated bacteria	Induces strong T cell-mediated immunity	10–15 years, with minimal efficacy in adults.	Booster not recommended due to inconsistent efficacy
Influenza (Flu Vaccine)	Influenza	Inactivated or live-attenuated	Induces strain-specific antibody response	6–12 months	Annual booster required due to viral mutation
Shingrix (Shingles Vaccine)	Herpes Zoster (Shingles)	Recombinant subunit	Induces strong T-cell and B-cell responses	>10 years	No booster currently recommended |
Pneumococcal (PCV13, PPSV23)	Pneumonia, Meningitis	Conjugate (PCV13) Polysaccharide (PPSV23)	Induces strong IgG response, enhanced in conjugate form	~10 years (PCV), ~5 years (PPSV23)	Booster recommended for high-risk groups
Meningococcal Vaccine	Meningitis	Conjugate or polysaccharide	Induces a strong B-cell response against meningococcal serogroups	~5–10 years	Booster required for high-risk individuals
COVID-19 (mRNA: Pfizer/Moderna, Viral Vector: AstraZeneca, J&J)	COVID-19	mRNA/Viral Vector	Induces strong humoral and cellular immunity	~6–12 months, variable	Booster required due to waning immunity and variants
Hepatitis A	Hepatitis A	Inactivated virus	Induces strong antibody-mediated immunity	At least 20 years, likely lifelong	No booster needed for most individuals
Rabies Vaccine	Rabies	Inactivated virus	Induces a strong neutralizing antibody response	~10 years with pre-exposure doses	Booster required for continued exposure (e.g., veterinarians)

prevent infections from causing disease, SIgA is essential. Unlike systemic IgG, which typically acts after infections have penetrated cellular barriers, sIgA intervenes early, preventing invasion before it occurs. In order to assess the effectiveness of mucosal vaccinations, especially against respiratory viruses such as influenza, RSV, and SARS-CoV-2, it has become possible to measure nasal sIgA titers. The development of such mucosal vaccines against gastrointestinal and respiratory infections, like intranasal COVID-19 vaccines, may thus enhance long-term immune protection by shifting production to a potent IgA responses.[89]

AQ1

Lifestyle and environmental factors

There are many different modulators in the vaccine efficacy spectrum, including exposure to pathogens, the composition of the gut microbiome, and diet. Whereas the gut microbiota controls immunity induced by vaccines, malnutrition with respect to vitamin A and zinc afflicts immune responses. Finally, booster vaccinations in undernourished people, coupled with supplementation with vitamins and probiotic-based vaccine adjuvants, may enhance immunity.[90]

FUTURE STRATEGIES FOR LONG-TERM VACCINE-INDUCED IMMUNITY

The provision of long-lasting vaccination-induced immunity in such populations is extraordinarily perplexing, particularly because of highly mutable pathogens, frailty of host immune systems, or some combination of the two. Vaccine intervention has indeed been spectacularly successful in eradicating or controlling infectious diseases, but newer problems such as waning immunity and antigenic variation and immune evasion require next-generation vaccine approach design.[91] The burgeoning horizon is the ecosystem for induced broad and potent immunity due to advances in delivery systems, biotechnology, and immunology. Among the more promising approaches is the development of universal vaccines against conserved sites of pathogens that would eliminate the need for updates and booster shots. For instance, the focus of universal influenza vaccine development is on a hemagglutinin stalk region that is better conserved, rather than the head region of the virus, which undergoes rapid mutations. Similarly, vaccinations designed to elicit widespread immune responses against coronaviruses being tested target the conserved S2 part of the spike protein.[92] Such universal vaccines could thereby promote long-term immune protection while drastically reducing the need for yearly reformulation. Consolidated antigen design with the help of computational and structural biology is a central strategy. The feasibility of identification of highly immunogenic and conserved epitopes gets borne out with new advances in reverse vaccinology and AI-driven antigen prediction.

Epitope accessibility is a crucial factor in the design of effective universal vaccines. It refers to the ability of an epitope, a specific region on an antigen that T cells and antibodies can recognize, to be exposed and available for interaction with the immune system. In the context of universal vaccines, which aim to be effective against a wide range of pathogen variants or strains, ensuring high epitope accessibility is essential for eliciting a broad and robust immune response.

Here's why epitope accessibility is important for universal vaccines:

Immune recognition

For an epitope to be effective in eliciting an immune response, it must be accessible to immune cells (T cells and B cells). If an epitope is hidden within the protein structure or buried within the pathogen's surface, it won't be recognized by the immune system, rendering the vaccine ineffective against a wide range of pathogens.

Universal vaccine design

Universal vaccines aim to target conserved regions of a pathogen that is less likely to mutate, thus providing protection against various strains. Epitope accessibility plays a key role in identifying these conserved regions. If an epitope is accessible across different strains, it becomes a promising target for a universal vaccine.

Vaccine effectiveness

The accessibility of an epitope directly impacts the vaccine's effectiveness. If an epitope is poorly accessible, it might lead to a weaker or narrower immune response, reducing the vaccine's ability to protect against diverse pathogen variants.

Designing for broad protection

When designing universal vaccines, scientists often use computational tools and experimental techniques to assess the accessibility of potential epitopes. This involves predicting the three-dimensional structure of the pathogen's proteins and identifying regions that are likely to be exposed on the surface.

In summary, epitope accessibility is a critical factor in the development of effective universal vaccines. By focusing on accessible and conserved epitopes, researchers can design vaccines that offer broad protection against a wide range of pathogens.

This has become crucial in the development of vaccines against complex diseases such as HIV and malaria, where traditional approaches have encountered challenges. By designing antigens with superior stability and immunogenicity attributes, researchers may produce vaccines that could elicit a strong and durable immunological memory. Long-lasting vaccine-induced immunity also heavily depends on next-generation adjuvants.[93] Conventional adjuvants, such as aluminum salts, might not induce potent T-cell responses but enhance humoral immunity. To concurrently evoke memory responses of B and T cells and provide long-lasting protection, a new generation of adjuvants is being developed, utilizing TLR agonists (like monophosphoryl lipid A MPL in Shingrix), saponin-based adjuvants (like QS-21), and nanoparticle-based adjuvants. In addition, these adjuvants

AQ1

augment the efficacy of immunization in the elderly population by counteracting age-associated immunological exhaustion. Heterologous prime-boost strategies that combine various vaccination platforms to provide broader, more robust protection are currently gaining traction. Intensive investigations have been carried out utilizing this strategy throughout COVID-19 vaccine campaigns, with mRNA vaccines (Pfizer, Moderna) and adenoviral-vectored vaccines (AstraZeneca, Sputnik V) demonstrating greater immune responses as combinations than homologous regimens.[94,95] These strategies have the ability to augment cross-protection against variants, promoting both humoral and cellular immunity. Long-term immunity based on a promising development in vaccination technology, mRNA, and self-amplifying RNA (saRNA) vaccines is within reach. While requiring several doses to induce protection, conventional mRNA vaccines induce robust immune responses. saRNA vaccines sustain expression of the antigen due to the encoded viral replication machinery, thus removing the need for booster doses. This approach is being explored for cancer immunotherapy as well as for vaccines against infectious diseases. Development of mucosal vaccination may grease the long-term immune response, especially pertinent against gastrointestinal and respiratory pathogens. Current vaccines are mostly delivered intramuscularly; such vaccinations yield great systemic immunity but poor mucosal protection. Strong mucosal IgA responses will be induced by intranasal or oral vaccines being developed for COVID-19, influenza, and TB, halting infection at their entry points. This not only further protects the community from infection by reducing the transmission of the virus but also enhances local Immunity.[96] In order to optimize vaccine efficacy across diverse demographic groups, personalization of vaccination strategies has gained popularity. Individual vaccine responses are affected by previous immunological encounters, genetics, and microbiome composition. Accordingly, growing networks of systems immunology and big data analytics allow researchers to personalize vaccine formulations and schedules based on an individual's immunogenetic profile, whereby higher doses, additional boosters, or other adjuvants may be beneficial for those whose responses are weaker due to specific HLA variants.[97] Another focus in this area is the nanotechnology-based vaccine delivery system that enhances immune stimulation and stability of the antigen. LNPs, once developed for the efficacious delivery of mRNA vaccines, are now being optimized to improve their ability to induce antigen presentation and prolong the activation of an immune response. Progress is also being made towards DC-targeting nanoparticles, polymer-based nanoparticles, and virus-like particles that boost antigen presentation and uptake and prolong vaccine persistence. To withstand the ever-changing components of microbial pathogens, epitope-based and multi-pathogen vaccines are under development to potentiate immune responses. Vaccines could immunologically escape by targeting conserved immunodominant regions as opposed to whole-protein antigens. Pentavalent and hexavalent vaccine formulations are examples of multi-pathogen vaccines that simultaneously protect against numerous diseases with a single dose, thereby improving coverage and lowering logistical barriers.[98] Bioengineering and synthetic biology are transforming traditional vaccine research. Programmable RNA vaccines, viral vector platforms, and mRNA-based vaccines each provide the ability for fast adaptability to novel pathogens.

CONCLUSION

The robustness of vaccine-induced protection relies on the sophisticated interplay between systemic and mucosal immune systems. As established in this review, the "secrets" of long-term immunity lie within the specialized pathways of MBCs, MTCs, and the long-term survival of plasma cells in the bone marrow niche. While the window of immunity loss remains, a challenge influenced by vaccine design and host factors, the evolution of vaccinology – transitioning from traditional live-attenuated platforms to modern mRNA and viral vector systems – offers a path toward more durable protection.

The signaling pathways and molecular processes, such as IL-21 and IL-2 mediated survival and GC affinity maturation, are now better understood, yet hurdles remain in achieving universal protection against rapidly mutating pathogens such as HIV and influenza. The implementation of heterologous prime-boost strategies, next-generation adjuvants, and personalized vaccine designs driven by AI and systems immunology will be pivotal in overcoming these barriers. Ultimately, by unraveling the mechanisms that govern the establishment and maintenance of immunological memory, the scientific community can develop next-generation vaccines that not only improve the breadth and duration of protection but also ensure global health security for diverse populations.

AUTHORS CONTRIBUTIONS

Saravanan Ravindran: Contributed to conceptualization, literature synthesis, and initial drafting. Performed formal analysis of included studies and critical evaluation, resource curation, and data validation. Shaik Farahan Subahan: Supervised the research design and finalized the manuscript. Reviewed, edited, and refined the intellectual content. All authors approved the final version and agreed to accountability for the work.

ACKNOWLEDGMENTS

Declared none.

AQ1

AQ5

REFERENCES

1. Pollard AJ, Bijker EM. A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol 2021;21:83-100.
2. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012;30:4907-20.
3. Syeda MZ, Hong T, Huang C, Huang W, Mu Q. B cell memory: From generation to reactivation: A multipronged defense wall against pathogens. Cell Death Discov 2024;10:117.
4. Buisman AM, De Rond CG, Öztürk K, Ten Hulscher HI, Van Binnendijk RS. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 2009;28:179-86.
5. Rosado MM, Scarsella M, Pandolfi E, Cascioli S, Giorda E, Chionne P, *et al*. Switched memory B cells maintain specific memory independently of serum antibodies: The hepatitis B example. Eur J Immunol 2011;41:1800-8.
6. Wang L, Nicols A, Turtle L, Richter A, Duncan CJ, Dunachie SJ, *et al*. T cell immune memory after COVID-19 and vaccination. BMJ Med 2023;2:e000468.
7. Todryk SM. T cell memory to vaccination. Vaccines (Basel) 2018;6:84.
8. Gray JI, Westerhof LM, MacLeod MK. The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination. Immunology 2018;154:574-81.
9. Gourley TS, Wherry EJ, Masopust D, Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 2004;16:323-33.
10. Miron M, Meng W, Rosenfeld AM, Dvorkin S, Poon MM, Lam N, *et al*. Maintenance of the human memory T cell repertoire by subset and tissue site. Genome Med 2021;13:100.
11. Reed S, Orr M, Fox C. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-608.
12. Chi WY, Li YD, Huang HC, Chan TE, Chow SY, Su JH, *et al*. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 2022;29:82.
13. Beukenhorst AL, Koch CM, Hadjichrysanthou C, Alter G, De Wolf F, Anderson RM, *et al*. SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: Implications for future vaccination strategies. Eur J Epidemiol 2023;38:237-42.

AQ6

14. Panari H, Anuchithra. Study on immunization among the mothers of under five children, Halaga village, Belgaum, Karnataka. Indian J Public Health Res Dev 2016;7:191-8.
15. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020;20:615-32.
16. Carsetti R, Tozzi AE. The role of memory B cells in immunity after vaccination. Paediatr Child Health 2009;19 Suppl 2:S160-2.
17. Chen S, Guan F, Candotti F, Benlagha K, Camara NO, Herrada AA, *et al*. The role of B cells in COVID-19 infection and vaccination. Front Immunol 2022;13:988536.
18. Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, *et al*. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol 2019;10:2458.
19. Facciolà A, Visalli G, Laganà A, Di Pietro A. An overview of vaccine adjuvants: Current evidence and future perspectives. Vaccines (Basel) 2022;10:819.
20. Lycke M, Bemark M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol 2010;3:556-66.
21. Korosec CS, Dick DW, Moyles IR, Watmouch J. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series. Sci Rep 2024;14:8426.
22. Seder R, Darrah PA, Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008;8:247-58.
23. Liu X, Li H, Li S, Yuan J, Pang Y. Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design. Front Immunol 2023;14:1100741.
24. Davis-Porada J, George AB, Lam N, Caron DP, Gray JI, Huang J, *et al*. Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues. Immunity 2024;57:2895-913.e8.
25. Esser MT, Marchese RD, Kierstead LS, Tussey LG, Wang F, Chirmule N, *et al*. Memory T cells and vaccines. Vaccine 2003;21:419-30.
26. Li F, Dang W, Du Y, Xu X, He P, Zhou Y, *et al*. Tuberculosis vaccines and T cell immune memory. Vaccines (Basel) 2024;12:483.
27. Carter D, Reed SG. Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS 2010; 5:409-13.
28. Wu Z, Liu K. Overview of vaccine adjuvants. Med Drug Discov 2021;11:100103.
29. Turley JL, Lavelle EC. Resolving adjuvant mode of action to enhance vaccine efficacy. Curr Opin Immunol 2022;77:102229.
30. Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. Vaccines (Basel) 2021;9:1490.
31. Wang C, Yuan F. A comprehensive comparison of DNA and RNA vaccines. Adv Drug Deliv Rev 2024;210:115340.
32. McCann N, O'Connor D, Lambe T, Pollard AJ. Viral vector vaccines. Curr Opin Immunol 2022;77:102210.
33. Minor PD. Live attenuated vaccines: Historical successes

and current challenges. Virology 2015;479-480:379-92.
34. Tangye SG, Tarlinton DM. Memory B cells: Matching supply with demand. Nat Rev Immunol 2009;9:327-38.
35. Hervé C, Laupèze B, Del Giudice G, *et al*. The how's and what's of vaccine adjuvants. Hum VaccinImmunother 2019;15:726-39.
36. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century Society. Nat Rev Immunol 2011;11:865-72.
37. Crommelin DJ, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci 2021;110:995-1001.
38. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17:261-79.
39. Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol 2021;21:195-7.
40. Shrestha LS, Shrestha R. Understanding the importance of booster doses in vaccine-induced immunity. Vaccines (Basel) 2023;11:345.
41. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012;30:429-57.
42. Lanzavecchia A, Sallusto F. Human B cell memory. Curr Opin Immunol 2009;21:298-304.
43. He Q, Mao Q, An C, *et al*. Heterologous prime-boost: A promising strategy for vaccination. Expert Rev Vaccines 2021;20:201-9.
44. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, *et al*. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022;386:1046-57.
45. Woodson SE, Reap EA, Beck AR, *et al*. Heterologous prime-boost vaccination strategies to improve cell-mediated immunity. Vaccine 2020;38:2456-65.
46. Pellegrino P, Clementi M, Radice S. On narcolepsy and the Pandemrix vaccine. Lancet 2013;381:446.
47. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861-80.
48. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: Antibody effector functions in infectious diseases. Nat Rev Immunol 2018;18:46-61.
49. Slifka MK, Ahmed R. Long-lived plasma cells and the persistence of humoral immunity. Curr Opin Immunol 1998;10:252-8.
50. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357:1903-15.
51. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 2010;33:451-63.
52. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, *et al*. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000;74:1948-60.
53. Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev 2013;254:207-24.
54. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, *et al*. Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect Dis 2006;6:641-52.
55. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011;12:509-17.
56. Bitton N, Schantz S, Grimaldi G, *et al*. Antibody responses to measles, mumps, and rubella vaccines. Vaccine 2015;33:2451-8.
57. Crotty S. Follicular helper CD_4 T cells (Tfh). Annu Rev Immunol 2011;29:621-63.
58. Sprent J, Surh CD. Normal T cell homeostasis: The conversion of naive cells into memory-phenotype cells. Nat Immunol 2011;12:478-84.
59. Masopust D, Soerens AG. Tissue-resident memory T cells and fixed immune surveillance. Synapse 2019;24:6-14.
60. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015;15:486-99.
61. Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol 2002;14:523-36.
62. Wack A, Baudner BC, Hammerschmidt S, *et al*. Adjuvants for mucosal vaccines: Current status and future perspectives. Expert Rev Vaccines 2008;7:547-61.
63. Mestecky J. The common mucosal immune system and current strategies for mucosal immunization. Mem Inst Oswaldo Cruz 2000;95 Suppl 1:153-7.
64. Brandtzaeg P. Induction of mucosal immunity and its role in host defense. Expert Rev Vaccines 2003;2:833-56.
65. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11 4 Suppl: S45-53.
66. Kaufmann SH. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007;5:491-504.
67. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013;368:551-60.
68. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-65.
69. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011;239:149-66.
70. Heaton PM. The role of the pharmaceutical industry in vaccine development and delivery. Health Aff (Millwood) 2005;24:655-63.
71. Bloom DE, Canning D, Weston M. The value of vaccination. World Econ 2005;6:15-39.
72. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013;14:428-36.
73. Lambert PH, Siegrist CA. Vaccine adjuvants: A key to the future of vaccination. Expert Rev Vaccines 2004;3:445-52.
74. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011;239:125-48.
75. Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: In the era of SARS-CoV-2. Front Immunol 2020;11:594503.

AQ1

76. Lavelle EC, Ward RW. Mucosal vaccines - fortifying the frontiers. Nat Rev Immunol 2022;22:236-50.
77. Krammer F, Palese P. Universal influenza virus vaccines: Need for a paradigm shift. Nat Rev Drug Discov 2015;14:167-82.
78. Pulendran B. Systems vaccinology: Probing humanity's immunity to vaccines and pathogens. Nat Rev Immunol 2014;14:789-99.
79. Tsang JS, Dobaño C, Helms M, *et al*. Improving vaccine-induced immunity: A systems biology approach. Cell 2020;183:15-28.
80. Hsiung KC, Chiang HJ, Reinig S, Shih SR. Vaccine strategies against RNA viruses: Current advances and future directions. Vaccines (Basel) 2024;12:1345.

AQ7

Source of Support: Nil. **Conflicts of Interest:** None declared.

Author Queries???
AQ1: Kindly provide running ttile
AQ2: Kindly provide department
AQ3: Kindly cite figures 1-5 in the text part
AQ4: Kindly check the reference citations 81-98 in the text part
AQ5: Kindly cite references 67-76 in text part
AQ6: Kindly provide author initial
AQ7: Kindly provide six authors before et al
AQ8: Kindly cite tables 1 and 2 in the text part